Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Metformin577 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A46645 | 16932311 | Nat Clin Pract Endocrinol Metab | Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. | 2006 | Details |
| A46661 | 16771968 | Am J Gastroenterol | Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease. | 2006 | Details |
| A46697 | 16456401 | J Pediatr Gastroenterol Nutr | Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children. | 2006 | Details |
| A46742 | 15990591 | Curr Opin Lipidol | Nonalcoholic fatty liver disease and the metabolic syndrome. | 2005 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |
| A46768 | 15727706 | Zhonghua Gan Zang Bing Za Zhi | [Drug therapy for nonalcoholic fatty liver disease]. | 2005 | Details |
| A46781 | 15611492 | Ann Intern Med | Narrative review: hepatobiliary disease in type 2 diabetes mellitus. | 2004 | Details |
| A46808 | 15151470 | Expert Rev Cardiovasc Ther | Treatment of metabolic syndrome. | 2004 | Details |
| A46830 | 14499793 | Am J Gastroenterol | Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. | 2003 | Details |
| A46855 | 12591075 | Am J Gastroenterol | Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. | 2003 | Details |
| A46860 | 12408779 | Curr Treat Options Gastroenterol | Therapeutic Options in Nonalcoholic Fatty Liver Disease. | 2002 | Details |
| A47050 | 27861855 | Int J Cancer | Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. | 2016 | Details |
| A47132 | 25400459 | World J Gastroenterol | Metformin does not improve survival in patients with hepatocellular carcinoma. | 2014 | Details |
| A47154 | 24797033 | Alcohol Clin Exp Res | Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. | 2014 | Details |
| A47770 | 32213649 | Endocrinol Diabetes Metab Case Rep | The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. | 2020 | Details |
| A47771 | 32203160 | Oncogene | NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin. | 2020 | Details |
| A47857 | 30759233 | J Clin Endocrinol Metab | Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue. | 2019 | Details |
| A47913 | 29411291 | Diabetes Ther | Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. | 2018 | Details |
| A48016 | 26486483 | Vnitr Lek | [Polycystic ovary syndrome]. | 2015 | Details |
| A48026 | 26123027 | Gut | Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome. | 2015 | Details |
| A48042 | 25866507 | Gastroenterol Res Pract | Treatment of nonalcoholic steatohepatitis in adults: present and future. | 2015 | Details |
| A48139 | 21800342 | Hepatology | Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis. | 2011 | Details |
| A48227 | 19183340 | Aliment Pharmacol Ther | Mechanism of action of metformin in nonalcoholic steatohepatitis. | 2009 | Details |
| A48321 | 16762632 | Gastroenterology | Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. | 2006 | Details |
| A48336 | 16219720 | J Clin Endocrinol Metab | Thyrotropin suppression by metformin. | 2005 | Details |
| A48375 | 14572592 | Am J Gastroenterol | Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment. | 2003 | Details |
| A48549 | 34267725 | Front Endocrinol (Lausanne) | Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. | 2021 | Details |
| A48713 | 30917505 | Int J Mol Sci | Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. | 2019 | Details |
| A48824 | 27498701 | Sci Rep | Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. | 2016 | Details |
| A48831 | 27158749 | Nat Rev Dis Primers | Hepatocellular carcinoma. | 2016 | Details |
| A48871 | 25954479 | World J Hepatol | Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? | 2015 | Details |
| A48933 | 24068196 | Int J Mol Med | Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice. | 2013 | Details |
| A49024 | 21088486 | Cell Cycle | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. | 2010 | Details |
| A49060 | 19646832 | Gastroenterol Clin Biol | Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. | 2009 | Details |
| A49096 | 17926479 | Ter Arkh | [Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety]. | 2007 | Details |
| A49187 | 14987322 | Aliment Pharmacol Ther | Metformin in the treatment of patients with non-alcoholic steatohepatitis. | 2004 | Details |
| A49210 | 35821558 | Curr Diab Rep | Lipodystrophy for the Diabetologist-What to Look For. | 2022 | Details |
| A49379 | 35769031 | Clin Transl Sci | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease. | 2022 | Details |
| A49435 | 35749136 | J Biomol Struct Dyn | Integrated multi-omic data analysis and validation with yeast model show oxidative phosphorylation modulates protein aggregation in amyotrophic lateral sclerosis. | 2022 | Details |
| A49506 | 35733070 | Mol Biol Rep | Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway. | 2022 | Details |
| A49679 | 35672633 | Environ Sci Pollut Res Int | Microarray analysis of mRNA expression profiles in liver of ob/ob mice with real-time atmospheric PM2.5 exposure. | 2022 | Details |
| A49704 | 35663787 | Int J Pediatr Adolesc Med | Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus. | 2021 | Details |
| A50126 | 35510444 | Phys Act Nutr | Pharmacological systemic analysis of gardenia fructus against non-alcoholic fatty liver disease and validation of animal models. | 2022 | Details |
| A50166 | 35494531 | Diabetes Metab Syndr Obes | Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. | 2022 | Details |
| A50259 | 35451807 | Curr Med Sci | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. | 2022 | Details |
| A50286 | 35443470 | J Assoc Physicians India | A Study of Correlation between Non Alcoholic Fatty Liver Disease and Carotid Atherosclerosis. | 2022 | Details |
| A50332 | 35430208 | Eur J Pharmacol | The lactate receptor GPR81 mediates hepatic lipid metabolism and the therapeutic effect of metformin on experimental NAFLDs. | 2022 | Details |
| A50383 | 35409465 | Int J Environ Res Public Health | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice. | 2022 | Details |
| A50466 | 35379885 | Sci Rep | Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway. | 2022 | Details |
| A50469 | 35378172 | J Hepatol | Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. | 2022 | Details |
| A50550 | 35344814 | Int Immunopharmacol | Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin. | 2022 | Details |
| A50611 | 35326230 | Antioxidants (Basel) | Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice. | 2022 | Details |
| A50797 | 35262903 | Dig Dis Sci | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. | 2022 | Details |
| A50810 | 35218717 | Eur J Pharmacol | HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca2+ relative signalling pathways. | 2022 | Details |
| A51019 | 25043205 | Hepatology | Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis. | 2014 | Details |
| A51049 | 20518098 | Nat Rev Endocrinol | Metformin, weight loss and NAFLD. | 2010 | Details |
| A51332 | 35535116 | J Clin Exp Hepatol | An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. | 2021 | Details |
| A51572 | 35008356 | Cancers (Basel) | A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. | 2021 | Details |
| A51575 | 34965034 | Acta Gastroenterol Belg | The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study. | 2021 | Details |
| A51672 | 35059746 | J Mol Med (Berl) | Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. | 2022 | Details |
| A51686 | 34920733 | Cardiovasc Diabetol | Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. | 2021 | Details |
| A51719 | 34629258 | Nutr Metab Cardiovasc Dis | Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. | 2021 | Details |
| A52017 | 32282852 | PLoS One | Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. | 2020 | Details |
| A52082 | 31559327 | GE Port J Gastroenterol | Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies. | 2019 | Details |
| A52164 | 30520016 | Int J Cancer | Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). | 2019 | Details |
| A52252 | 29681858 | Front Pharmacol | Aqueous Extract of Black Maca Prevents Metabolism Disorder via Regulating the Glycolysis/Gluconeogenesis-TCA Cycle and PPARα Signaling Activation in Golden Hamsters Fed a High-Fat, High-Fructose Diet. | 2018 | Details |
| A52357 | 28222147 | PLoS One | The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state. | 2017 | Details |
| A52447 | 27057099 | Mediators Inflamm | Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. | 2016 | Details |
| A52519 | 26101431 | Arch Dis Child | Optimal management of polycystic ovary syndrome in adolescence. | 2015 | Details |
| A52589 | 25294945 | Diabetes | Anti-CD44 antibody treatment lowers hyperglycemia and improves insulin resistance, adipose inflammation, and hepatic steatosis in diet-induced obese mice. | 2014 | Details |
| A52805 | 21536228 | Gend Med | Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type 2 diabetic patients. | 2011 | Details |
| A52827 | 21199519 | J Gastroenterol Hepatol | Hepatic steatosis and hepatitis C: Still unhappy bedfellows? | 2011 | Details |
| A52934 | 19349323 | Circulation | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. | 2009 | Details |
| A52997 | 18154189 | Clin Cornerstone | Metabolic consequences of hyperglycemia and insulin resistance. | 2007 | Details |
| A53043 | 16669279 | MMW Fortschr Med | [Secondary dyslipoproteinema in liver disease]. | 2006 | Details |
| A53085 | 15262452 | Clin Ther | A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. | 2004 | Details |
| A53107 | 12930161 | Drugs | Metformin: new understandings, new uses. | 2003 | Details |